Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
Exelon Patch | Rivastigmine | Dementia (Alzheimer's type) | Do not list | Complete | ||
Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | Do not list | Complete | ||
Rasilez | Aliskiren | Hypertension | Do not list | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder, Adult | Do not list | Complete | ||
Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | ||
Isentress | Raltegravir | HIV | List with clinical criteria and/or conditions | Complete | ||
Celsentri | Maraviroc | HIV | Withdrawn | |||
Invega | Paliperidone | Schizophrenia | Do not list | Complete |